Mersana Therapeutics Inc., of Cambridge, Mass., set terms for its IPO, aiming to raise $75 million through the sale of 5 million shares at a price range between $14 and $16. J.P. Morgan, Cowen & Co. and Leerink Partners are the joint bookrunners on the deal.